HRR Pediatric Matching Kit
Navigation Links
HRR Pediatric Matching Kit
| Products | HRR Pediatric Matching Kit |
| Company | Richmond Products, Inc. |
| Item | HRR Pediatric Matching Kit |
| Features | |
| Description | This kit consists of a Matching Card, three HRR symbol cards and instructions. Kit is intended to help prepare a child for subsequent HRR 4th Edition color testing. There are several ways to use the test. For the youngest patients, the parents can borrow the kit and help the child learn the concept of matching and become familiar with the HRR symbols. Once the child has mastered the matching concept, the matching card can be used during the color vision test to permit the child to identify which symbols they see on each of the HRR plates without touching the HRR plates. In this way, the kit helps prevent damage from childrens fingerprints on the HRR test plates. The cards are laminated for many years of use. |
| Info | Richmond Products, Inc. Customer Service: 505-275-2406 Web site: http://www.richmondproducts.com |
1-866-435-4770Related medicine products :
1. McNeil-Goldman Scleral and Blepharostat Ring - Pediatric
2. Cook Eye Speculum - Pediatric
3. Kratz-Barraquer Eye Speculum - Pediatric
4. Barraquer Pediatric Speculum - Solid Blade
5. Barraquer Pediatric Speculum - Wire Blade
6. Barraquer Eye Speculum - Pediatric
7. Pediatric Ostrum Antrum Punch Forceps
8. Pediatric Rotating Ostrum Antrum Punch Forceps
9. Pediatric Combination Eye Garter Shield Cover and Fox Shield
10. Pediatric Corneal Shields 10/Box
11. Ishihara Test Unlettered Pediatric 10 Plate Book
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels.
Lyphochek Benzo/TCA Control Set B is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and antidepressant drugs.
Lyphochek Whole Blood Metals Control contains the major heavy metals of toxicological and environmental importance for whole blood analysis.
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing.
Medicine Products:(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Begins -,...- Watson,Pharmaceuticals, Inc. (NYSE: WPI ), a le...today that its subsidiary has commenced commercial...es USP product in the 40mg,strength from its Davie...ith the launch, Watson has 180 days of marketing e...
(Date:7/25/2008)...URG, Ill., July 25 /PRNewswire/ -- Sagent Pharmace...utical company, today announced that it,has launch...arrhythmic,indicated for the treatment and prophyl...ion and hemodynamically unstable ventricular,tachy... heart beat.,Sagent,s amiodarone HCl injection wil...
(Date:7/25/2008)...D, Calif., July 25 /PRNewswire/ -- AutoGenomics, I...on statement on Form S-1 with the,Securities and E...l public,offering of shares of its common stock. T... all of which are expected to be offered by,AutoGe..., have not yet been,determined., J.P. Morgan Secu...
(Date:7/25/2008)... New program delivers immediate cost...4-hour telephone access to language interpreters] ...multilingual solutions. , ...E® http://www.lle-inc.com/index.html [(Langu...er of interpretation, translation, and language in...
Breaking Medicine News(10 mins):Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 3...ns and it is considered as an important factor to ...d cholesterol (low density lipoprotein-LDL) and ot...after the new study conducted by Dr. Frank M. Sack...vard School of Public Health, all the claims about...
...now being called the elixir of health. New studies...t eating more fruit and vegetables could let you l...five portions a day can reduce the risk of stroke ...searchers said the high levels of potassium, folat...
...tems are poor may get new hope from a research stu... which may result in improved stem cell therapies....// Paul Frenette has discovered that a critical r...ing the bone marrow stem cells into the human bloo...
... massive study concerning the bird flu virus genom...ude Children's Research Hospital. This has served ...e proteins// and genes of these viruses by about ...fears of a large scale pandemic across the world. ...
Other Medicine News:Health News:Re-evaluation of the soy protein’s effects to reduce cholestero 2(Date:7/23/2008)...E, July 23 /- Dendreon Corp...xpects the Independent Data,Monitoring Committee (...is,of overall survival relating to the Company,s P...cinoma Treatment, also known as D9902B) clinical t...e Company,s investigational,active cellular immuno...
(Date:7/22/2008)...ng efficacy results from a multi-center 293-patien... Toronto Stock Exchange Symbol: CYT, MONTREAL, Ju...ogies,Inc., the global leader in cryotherapy produ...that results previously presented from three,Europ..., Arctic Front(R),were published earlier today in...
(Date:7/22/2008)... Meeting to Discuss Development Plan Completed Suc...irstCall/ -- Amarin Corporation,plc (NASDAQ: AMRN...ith,officials at the U.S. Food and Drug Administra...op AMR101 for the treatment of,hypertriglyceridemi...ceeding to Phase 3 with AMR101 in hypertriglycerid...
(Date:7/22/2008)...imens Including Lantus(R) and Apidra(R) Resulted i...Type 2 Diabetes, Whatever the Algorithm ...uly 22 /- Results from the "Adjust to... Algorithm to Carbohydrate,Counting for Adjustment...hed in the American Diabetes Association,s (ADA) m...
Breaking Medicine Technology:Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4March of Dimes Announces Nursing Scholarship Recipients 23384 1March of Dimes Announces Nursing Scholarship Recipients 23384 2March of Dimes Announces Nursing Scholarship Recipients 23384 3March of Dimes Announces Nursing Scholarship Recipients 23384 4Biodiversity maps developed by UCSD scientists will help guide conservation measures in East Africa 3920 1Biodiversity maps developed by UCSD scientists will help guide conservation measures in East Africa 3920 2Biodiversity maps developed by UCSD scientists will help guide conservation measures in East Africa 3920 3Zix Corporation Announces Webcast Showcasing Email Encryption Competitive Replacement 23376 1Zix Corporation Announces Webcast Showcasing Email Encryption Competitive Replacement 23376 2Researchers reveal types of genes necessary for brain development 3919 1Researchers reveal types of genes necessary for brain development 3919 2[0] Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October[0] CryoCath Arctic Front(R) Results Published in JACC[0] Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia[0] Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
...K, April 10, 2007 /PRNewswire-FirstCall/ -- ImClon...mpany today,announced that a Phase III study of ER...apy) in patients with locally advanced,unresectabl...,primary endpoint of improving overall survival. ,... a cancer,center network sponsored by the National...
...TO, Calif., April 09, 2007 /PRNewswire-FirstCall/ ...a from its,multicenter Phase 2 trial of the triple...286), carboplatin and paclitaxel will be,presented...ation,for Cancer Research (AACR) in Los Angeles. P...lates of synergistic cancer cell growth,inhibition...
Other Medicine Technology:Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 2Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 3Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 4Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 5Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 6Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 7Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 8Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 9Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting 2Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting 3| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |